Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631262 | 0.93 | SLC6A3 (0.43) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL3466586 | 0.90 | L3MBTL1 (0.38) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL7676368 | 0.87 | MEN1 (0.38) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL5199433 | 0.84 | KDM4C (0.38) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL7674634 | 0.84 | L3MBTL1 (0.40) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL8316137 | 0.84 | SLC6A3 (0.45) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL8350985 | 0.83 | KDM4C (0.49) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL9053699 | 0.82 | SLC6A3 (0.44) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL5858706 | 0.81 | SLC6A3 (0.42) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 | |
| SCHEMBL6579345 | 0.81 | SLC6A3 (0.45) | SLC6A3KDM4CSLC6A2SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1923391-A1 | Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
| EP-1688416-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | Sanofi-Aventis (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-7053213-B2 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2006-05-30 | — | — | US | disclosed |
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| EP-1156049-B1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | SANOFI AVENTIS (FR) | 2005-06-01 | — | — | EP | disclosed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1077942-B1 | CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-0888338-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0994876-B1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| US-5411971-A | N-alkylenepiperidino compounds, their enantiomers and pharmaceutical compositions | ELF SANOFI (FR) | 1995-05-02 | — | — | US | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| US-5350852-A | Neurokinin A receptor antagonist | SANOFI (FR) | 1994-09-27 | — | — | US | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
| EP-0591040-A1 | Quaternary basic amides as tachykinines antagonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-5236921-A | Administrering for treatment of neutrogenic inflammation of the respiratory trart | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
| EP-0515240-A1 | N-alkylidene piperidine compounds and their enatiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | SLC6A3 2785/4885KDM4C 3515/4885SLC6A2 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.